戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ihydrotestosterone, cyproterone acetate, and hydroxyflutamide.
2  such as 100 nM 17beta-estradiol or 1 microM hydroxyflutamide.
3 atment with the specific androgen antagonist hydroxyflutamide.
4 esence of 10 nM 17beta-estradiol or 1 microM hydroxyflutamide.
5 y the anti-androgens cyproterone acetate and hydroxyflutamide.
6 y a competition assay with the anti-androgen hydroxyflutamide.
7 one, which was abolished by an anti-androgen hydroxyflutamide.
8 c prostate cancer drugs bicalutamide (1) and hydroxyflutamide (2) in reporter gene assays measuring t
9 0, an MRP1 modulator, restored flutamide and hydroxyflutamide accumulation.
10 A pathway could not be blocked completely by hydroxyflutamide, an antiandrogen used in the treatment
11  is consistent with previous SAR results for hydroxyflutamide analogues.
12 drostenediol-induced AR transactivation that hydroxyflutamide and bicalutamide failed to block.
13 erone) and antagonists (cyproterone acetate, hydroxyflutamide and bicalutamide).
14 red with commonly used antiandrogens such as hydroxyflutamide and bicalutamide, leading to a lower po
15 sn705 is an important determinant in binding hydroxyflutamide and its derivatives by participating in
16 reported structure-activity relationship for hydroxyflutamide and its derivatives.
17 1FxxLF peptide interaction, while flutamide, hydroxyflutamide, and bicalutamide caused only partial d
18 ompounds associated with iDILI; flutamide, 2-hydroxyflutamide, and tolcapone, and their less toxic co
19 susceptibility to inhibition by flutamide, 2-hydroxyflutamide, and tolcapone, via effects on selected
20 aring bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroid
21 -hybrid assay, we report that antiandrogens, hydroxyflutamide, bicalutamide (casodex), cyproterone ac
22                        An antagonist ligand, hydroxyflutamide, blocked the NTD-LBD association within
23 nically important antiandrogens, casodex and hydroxyflutamide, both D36 and D80 block androgen action
24 nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen re
25 y, these studies indicate that flutamide and hydroxyflutamide but not dihydrotestosterone are transpo
26                 Under permissive conditions, hydroxyflutamide competes poorly for the synthetic andro
27 ens including enzalutamide, bicalutamide, or hydroxyflutamide, could suppress nAR-negative BCa cell i
28 m for the enantioselective binding of chiral hydroxyflutamide derivatives and expand upon the previou
29  activity and that two potent antiandrogens, hydroxyflutamide (Eulexin) and bicalutamide (Casodex), f
30            Because two potent antiandrogens, hydroxyflutamide (Eulexin), and bicalutamide (casodex),
31 uired because the AR antagonists casodex and hydroxyflutamide failed to translocate beta-catenin.
32 sterone, 10 nM 17beta-estradiol, or 1 microM hydroxyflutamide for the LNCaP mutant AR (mtAR T877A), f
33 tingly, these compounds, in combination with hydroxyflutamide, further suppressed the Adiol-induced A
34                                      Whereas hydroxyflutamide (HF) has been used as an antiandrogen t
35                                 In contrast, hydroxyflutamide (HF), an antiandrogen currently used to
36   Because ARA70 can promote the antiandrogen hydroxyflutamide (HF)-enhanced AR transactivation, the i
37 e or 10(-9) M testosterone, but not 10(-6) M hydroxyflutamide in human prostate cancer DU145 cells.
38 backbone oxygen of Leu-873 and the ketone of hydroxyflutamide is present when bound to the T877A AR v
39  in efflux and accumulation of flutamide and hydroxyflutamide, its active metabolite.
40 o testosterone, the binding modes of several hydroxyflutamide-like nonsteroidal ligands for the andro
41 y observed and activated by bicalutamide and hydroxyflutamide, respectively, in prostate cancer patie
42              Although usually an antagonist, hydroxyflutamide was more potent in the recruitment of D
43 ctive conditions in the hsp82 mutant strain, hydroxyflutamide was shown to be a potent competitive in
44 tiandrogenic activities and were superior to hydroxyflutamide, which is the currently available antia